Leqvio Shortage: What Providers and Prescribers Need to Know in 2026

For prescribers managing patients with hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), or atherosclerotic cardiovascular disease (ASCVD), Leqvio (inclisiran) represents a significant clinical tool — but navigating its access pathway requires understanding the drug's unique delivery model. This guide covers everything providers need to know about Leqvio availability and administration in 2026.

Is Leqvio Actually in Shortage?

As of 2026, Leqvio (inclisiran) is not on the FDA's official drug shortage database. Novartis maintains stable manufacturing and distribution of the 284 mg/1.5 mL prefilled syringe formulation. The drug recorded $754 million in global 2024 revenue, with a growing U.S. provider base. There is no supply-side shortage.

However, patient access challenges remain real. The barriers are systemic and administrative, not supply-based:

• Prior authorization requirements from commercial and Medicare Advantage payers
• Step therapy requirements mandating trials of statins and/or ezetimibe first
• Inconsistent stocking across practice settings (particularly in primary care)
• Buy-and-bill billing complexity creating hesitation among smaller practices

Clinical Profile: Who Is an Appropriate Leqvio Candidate?

Leqvio is FDA-approved for adults with primary hyperlipidemia, including:

• Heterozygous familial hypercholesterolemia (HeFH)
• Clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C reduction
• Patients with primary hyperlipidemia who are statin-intolerant or have not achieved LDL-C targets on maximally tolerated statin therapy

Leqvio can be used as monotherapy or in combination with statins. There is no longer a requirement to first try maximum-dose statins before initiating Leqvio — it can be used first-line for appropriate patients. In clinical trials (ORION program), Leqvio reduced LDL-C by 40–51% from baseline at Day 510.

Dosing and Administration Requirements

Leqvio is administered as a 284 mg subcutaneous injection (1.5 mL prefilled syringe). The dosing schedule is:

1. Initial dose (Day 1)
2. Second dose at Day 90 (3 months)
3. Maintenance doses every 6 months thereafter

If a dose is missed by more than 3 months, restart the dosing schedule from the beginning. The injection is given subcutaneously in the abdomen, upper arm, or thigh, and must not be administered into damaged, bruised, or infected skin. Patients cannot self-administer Leqvio — it must be given by a healthcare professional.

Navigating Prior Authorization for Leqvio

Prior authorization is required by most commercial payers for Leqvio. Key documentation to include in your PA submission:

• Confirmed diagnosis of HeFH (genetic or clinical) or ASCVD with relevant ICD-10 codes
• Current LDL-C value (most payers require ≥70 mg/dL for ASCVD; ≥100 mg/dL for primary prevention depending on plan)
• Documentation of current statin therapy (or documented intolerance with at least two trials at various doses)
• Indication-specific notes justifying step beyond statins or ezetimibe

Cigna's policy (effective 02/01/2026) requires prior authorization for all Leqvio requests. UnitedHealthcare covers Leqvio under the medical benefit for confirmed HeFH or clinical ASCVD. Medicare has no national coverage determination (NCD) but generally covers Leqvio under Part B as a physician-administered drug.

Buy-and-Bill Billing: Key Practical Points

Leqvio is billed under the medical benefit using HCPCS code J1306 for the drug and a separate administration CPT code. The buy-and-bill model means your practice purchases the drug from a specialty distributor or through Novartis's purchasing program, administers it, and then bills the payer.

Per Novartis data, 92% of patients with insurance have confirmed medical benefit coverage for Leqvio, and 75% of commercial patients pay less than $10 per treatment. Practices setting up Leqvio administration should work with their billing team and the Leqvio Service Center (1-833-537-8462) to ensure proper claims workflows.

How medfinder Supports Your Patients' Access

When patients face delays in finding a Leqvio-administering provider, medfinder for providers helps by calling clinics to locate where the drug is available and conveying results to patients. This reduces the administrative burden on your staff and helps patients get their injections scheduled faster.

See our guide on how to help your patients find Leqvio in stock for a practical provider's reference.